Prediction/NN
Model/NN
for/IN
the/DT
Cellular/JJ
Immortalization/NN
and/CC
Transformation/NN
Potentials/NNS
of/IN
Cell/NN
Substrates/NNS
./.
====================
The/DT
establishment/NN
of/IN
DNA/NN
microarray/NN
technology/NN
has/VBZ
enabled/VBN
high-throughput/JJ
analysis/NN
and/CC
molecular/JJ
profiling/NN
of/IN
various/JJ
types/NNS
of/IN
cancers/NNS
./.
====================
By/IN
using/VBG
the/DT
gene/NN
expression/NN
data/NNS
from/IN
microarray/NN
analysis/NN
we/PRP
are/VBP
able/JJ
to/TO
investigate/VB
diagnostic/JJ
applications/NNS
at/IN
the/DT
molecular/JJ
level/NN
./.
====================
The/DT
most/JJS
important/JJ
step/NN
in/IN
the/DT
application/NN
of/IN
microarray/NN
technology/NN
to/TO
cancer/NN
diagnostics/NNS
is/VBZ
the/DT
selection/NN
of/IN
specific/JJ
markers/NNS
from/IN
gene/NN
expression/NN
profiles/NNS
./.
====================
In/IN
order/NN
to/TO
select/VB
markers/NNS
of/IN
immortalization/NN
and/CC
transformation/NN
we/PRP
used/VBD
c-myc/NN
and/CC
H-ras/NN
oncogene-transfected/VBN
NIH3T3/NN
cells/NNS
as/IN
our/PRP$
model/NN
system/NN
./.
====================
We/PRP
have/VBP
identified/VBN
8751/CD
differentially/RB
expressed/VBN
genes/NNS
in/IN
the/DT
immortalization/transformation/NN
model/NN
by/IN
multivariate/JJ
permutation/NN
F-test/JJS
(/(
95/CD
%/NN
confidence/NN
,/,
FDR/NN
</JJR
0.01/CD
)/)
./.
====================
Using/VBG
the/DT
support/NN
vector/NN
machine/NN
algorithm/NN
,/,
we/PRP
selected/VBD
13/CD
discriminative/JJ
genes/NNS
which/WDT
could/MD
be/VB
used/VBN
to/TO
predict/VB
immortalization/NN
and/CC
transformation/NN
with/IN
perfect/JJ
accuracy/NN
./.
====================
We/PRP
assayed/VBD
H-/NN
ras/NN
-transfected/JJ
“/CD
transformed/VBN
”/CD
cells/NNS
to/TO
validate/VB
our/PRP$
immortalization/transformation/NN
classification/NN
system/NN
./.
====================
The/DT
selected/VBN
molecular/JJ
markers/NNS
generated/VBN
valuable/JJ
additional/JJ
information/NN
for/IN
tumor/NN
diagnosis/NN
,/,
prognosis/NN
and/CC
therapy/NN
development/NN
./.
====================
Cell/NN
substrates/NNS
can/MD
be/VB
used/VBN
to/TO
produce/VB
recombinant/JJ
====================
vaccines/NNS
or/CC
proteins/NNS
for/IN
therapeutics/NNS
./.
====================
Although/IN
the/DT
number/NN
of/IN
residual/JJ
cells/NNS
,/,
substrates/NNS
and/CC
adventitious/JJ
materials/NNS
is/VBZ
usually/RB
minimal/JJ
in/IN
the/DT
final/JJ
products/NNS
,/,
we/PRP
need/VBD
to/TO
check/VB
whether/IN
these/DT
substances/NNS
can/MD
lead/VB
to/TO
transformation/NN
and/CC
tumors/NNS
in/IN
recipients/NNS
./.
====================
To/TO
check/VB
the/DT
tumorigenic/JJ
potential/JJ
of/IN
cell/NN
substrates/NNS
,/,
it/PRP
is/VBZ
necessary/JJ
to/TO
check/VB
the/DT
tumorigenicity/NN
in/IN
vivo/FW
using/VBG
immunocomprimized/VBN
animal/NN
models/NNS
such/JJ
as/IN
Balb/c-nu/NNP
mice/NNS
./.
====================
However/RB
,/,
these/DT
methods/NNS
are/VBP
time/NN
consuming/VBG
and/CC
expensive/JJ
making/VBG
it/PRP
impractical/JJ
to/TO
test/VB
cell/NN
substrates/NNS
candidates/NNS
in/IN
this/DT
way/NN
./.
====================
By/IN
using/VBG
biomarkers/NNS
for/IN
cellular/JJ
transformation/NN
we/PRP
can/MD
classify/VB
cell/NN
substrates/NNS
according/VBG
to/TO
their/PRP$
transforming/VBG
potentials/NNS
without/IN
the/DT
need/NN
for/IN
costly/RB
animal/NN
testing/NN
./.
====================
Normal/JJ
diploid/JJ
cells/NNS
can/MD
divide/VB
a/DT
limited/JJ
number/NN
of/IN
times/NNS
before/IN
entering/VBG
into/IN
an/DT
irreversible/JJ
growth/NN
arrest/NN
termed/VBN
replicative/JJ
senescence/NN
(/(
Hayflick/NN
,/,
1965/CD
)/)
./.
====================
A/DT
small/JJ
percentage/NN
of/IN
cells/NNS
can/MD
acquire/VB
unlimited/JJ
proliferation/NN
potential/JJ
,/,
which/WDT
is/VBZ
a/DT
key/JJ
step/NN
in/IN
tumorigenesis/NN
(/(
Greider/NN
,/,
1999/CD
)/)
./.
====================
Telomerase/DT
activity/NN
has/VBZ
been/VBN
reported/VBN
to/TO
be/VB
sufficient/JJ
to/TO
immortalize/VB
human/JJ
diploid/JJ
fibroblasts/NNS
(/(
Bodnar/JJ
et/FW
al./FW
,/,
1998/CD
)/)
,/,
while/IN
other/JJ
studies/NNS
have/VBP
shown/VBN
that/IN
the/DT
c~myc/NN
oncogene/NN
fulfils/VBZ
many/JJ
of/IN
the/DT
criteria/NNS
for/IN
a/DT
gene/NN
involved/VBN
in/IN
the/DT
immortalization/NN
of/IN
human/JJ
epithelial/JJ
cells/NNS
(/(
Bouchard/NNP
et/FW
al./FW
,/,
1998/CD
)/)
./.
====================
Signaling/NN
from/IN
the/DT
small/JJ
GTPase/NN
,/,
Ras/NN
,/,
has/VBZ
been/VBN
under/IN
intense/JJ
investigation/NN
over/IN
the/DT
past/NN
decade/NN
due/JJ
to/TO
its/PRP$
involvement/NN
in/IN
mediating/VBG
the/DT
pathways/NNS
that/WDT
control/NN
transcriptional/JJ
activation/NN
./.
====================
The/DT
pathways/NNS
include/VBP
mediators/NNS
of/IN
critical/JJ
and/CC
diverse/JJ
cellular/JJ
functions/NNS
such/JJ
as/IN
proliferation/NN
,/,
development/NN
,/,
differentiation/NN
,/,
and/CC
apoptosis/NN
(/(
Ayllon/NN
and/CC
Rebollo/NN
,/,
2000/CD
)/)
./.
====================
Mutations/NNS
conferring/VBG
constitutive/JJ
activation/NN
of/IN
Ras/NN
occur/VBP
frequently/RB
in/IN
many/JJ
types/NNS
of/IN
human/JJ
cancers/NNS
(/(
Bos/NNS
,/,
1989/CD
)/)
./.
====================
Signaling/NN
pathways/NNS
downstream/RB
of/IN
Ras/NN
have/VBP
been/VBN
fairly/RB
well/RB
defined/VBN
,/,
and/CC
their/PRP$
contribution/NN
to/TO
Ras-/NN
mediated/VBN
transformation/NN
has/VBZ
been/VBN
studied/VBN
extensively/RB
./.
====================
With/IN
the/DT
aim/NN
of/IN
reconstructing/VBG
tumorigenesis/NN
,/,
we/PRP
have/VBP
used/VBN
mouse/NN
fibroblast/NN
NIH3T3/NN
cells/NNS
to/TO
establish/VB
models/NNS
for/IN
immortalization/NN
and/CC
transformation/NN
by/IN
c~myc/NN
and/or/CC
H-ras/NN
V12/NN
./.
====================
The/DT
gene/NN
expression/NN
profiles/NNS
of/IN
these/DT
cells/NNS
were/VBD
analyzed/VBN
by/IN
Affymetrix/JJ
microarray/NN
to/TO
find/VB
differentially/RB
expressed/VBN
genes/NNS
in/IN
each/DT
group/NN
./.
====================
Finally/RB
,/,
we/PRP
selected/VBD
13/CD
genes/NNS
which/WDT
could/MD
be/VB
used/VBN
to/TO
predict/VB
whether/IN
the/DT
tested/VBN
cells/NNS
were/VBD
normal/JJ
,/,
immortalized/VBN
or/CC
transformed/VBN
with/IN
one/CD
hundred/VBN
percent/NN
accuracy/NN
./.
====================
These/DT
genes/NNS
and/CC
algorithm/NN
may/MD
be/VB
useful/JJ
in/IN
the/DT
classification/NN
of/IN
cell/NN
substrates/NNS
to/TO
predict/VB
their/PRP$
transforming/VBG
potential/JJ
without/IN
the/DT
need/NN
for/IN
in/IN
vivo/FW
tumorigenicity/NN
assays/NNS
./.
====================
NIH3T3/NN
mouse/NN
fibroblast/NN
cells/NNS
were/VBD
maintained/VBN
in/IN
====================
DMEM/NN
supplemented/VBN
with/IN
10/CD
%/NN
FBS/NN
and/CC
antibiotics/NNS
of/IN
penicillin/streptomycin/NN
at/IN
37/CD
°C/NN
in/IN
a/DT
humidified/JJ
incubator/NN
====================
with/IN
a/DT
5/CD
%/NN
CO/NN
2/CD
atmosphere/VBP
./.
====================
We/PRP
established/VBD
stable/JJ
====================
NIH3T3/NN
(/(
c-myc/NN
)/)
cell/NN
lines/NNS
by/IN
transfecting/VBG
NIH3T3/NN
cells/NNS
with/IN
pcDNAc-myc/NN
using/VBG
Lipofectamine/JJ
(/(
Invitrogen/NN
,/,
USA/NNP
)/)
and/CC
selecting/VBG
stable/JJ
transfectants/NNS
with/IN
Geneticin/NN
(/(
Invitrogen/NN
,/,
USA/NNP
)/)
./.
====================
The/DT
other/JJ
cell/NN
lines/NNS
like/IN
NIH3T3/NN
(/(
H-/NN
ras/NN
V12/NN
)/)
and/CC
NIH3T3/NN
(/(
c-myc+H-ras/NN
V12/NN
)/)
were/VBD
established/VBN
using/VBG
the/DT
same/JJ
procedure/NN
./.
====================
The/DT
expressions/NNS
of/IN
transgenes/NNS
was/VBD
checked/VBN
by/IN
Western/NN
blot/NN
analysis/NN
(/(
data/NNS
not/RB
shown/VBN
)/)
,/,
and/CC
the/DT
in/FW
vitro/FW
and/CC
in/IN
vivo/FW
transformation/NN
potential/JJ
of/IN
cells/NNS
was/VBD
checked/VBN
using/VBG
soft/JJ
agar/NN
assays/NNS
and/CC
by/IN
tumor/NN
formation/NN
assays/NNS
in/IN
Balb/c-nu/NNP
mouse/NN
,/,
respectively/RB
./.
====================
Total/JJ
RNAs/NNS
from/IN
cells/NNS
was/VBD
extracted/VBN
using/VBG
Trizol/NN
reagent/JJ
(/(
Invitrogen/NN
Inc./NNP
,/,
USA/NNP
)/)
and/CC
purified/VBN
by/IN
column/NN
chromatography/NN
(/(
RNeasy/NN
,/,
Qiagen/NN
)/)
according/VBG
to/TO
the/DT
protocol/NN
provided/VBD
by/IN
the/DT
manufacturer/NN
./.
====================
The/DT
quality/NN
of/IN
RNA/NN
was/VBD
checked/VBN
by/IN
quantifying/VBG
260/280/CD
and/CC
260/230/CD
ratios/NNS
and/CC
by/IN
gel/NN
electrophoresis/NN
(/(
data/NNS
not/RB
shown/VBN
)/)
./.
====================
Following/VBG
ethanol/NN
precipitation/NN
,/,
RNA/NN
was/VBD
stored/VBN
at/IN
-80/CD
°C/NN
after/IN
ethanol/NN
precipitation/NN
./.
====================
Labeling/VBG
and/CC
hybridization/NN
was/VBD
performed/VBN
as/IN
described/VBN
in/IN
Affymetrix/JJ
microarray/NN
protocol/NN
(/(
Kim/NN
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
The/DT
array/NN
used/VBN
in/IN
this/DT
experiment/NN
was/VBD
Affymetrix/JJ
mouse/NN
genome/NN
430/CD
2.0/CD
array/NN
which/WDT
includes/VBZ
39,000/CD
transcripts/NNS
./.
====================
Many/JJ
experiments/NNS
for/IN
control/NN
,/,
c-myc/NN
,/,
H-ras/NN
V12/NN
,/,
and/CC
c-myc+H-ras/NN
V12/NN
microarray/NN
experiment/NN
were/VBD
quadruplicated/VBN
producing/VBG
a/DT
total/JJ
of/IN
16/CD
sets/NNS
of/IN
microarray/NN
data/NNS
./.
====================
Fluorescence/NN
intensity/NN
was/VBD
processed/VBN
and/CC
measured/VBD
using/VBG
GeneChip/NN
scanner/NN
3000/CD
and/CC
intensity/NN
data/NNS
was/VBD
imported/VBN
to/TO
an/DT
in-house/JJ
microarray/NN
database/NN
./.
====================
In/IN
order/NN
to/TO
normalize/VB
data/NNS
and/CC
remove/VBP
systemic/JJ
variance/NN
,/,
RMA/NN
(/(
Robust/NNP
Multi/JJ
Array/NN
Average/NN
)/)
normalization/NN
was/VBD
applied/VBN
to/TO
remove/VB
systematic/JJ
variance/NN
(/(
Irizarry/NNP
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
The/DT
application/NN
of/IN
RMA/NN
allowed/VBD
the/DT
raw/NN
intensity/NN
values/NNS
to/TO
be/VB
background/JJ
corrected/VBD
,/,
Iog2/NN
transformed/VBN
and/CC
then/RB
quantile/RB
normalized/VBN
./.
====================
A/DT
linear/JJ
model/NN
was/VBD
fitted/VBN
to/TO
the/DT
normalized/VBN
data/NNS
to/TO
obtain/VB
an/DT
expression/NN
measurement/NN
for/IN
each/DT
probe/NN
set/NN
on/IN
each/DT
array/NN
./.
====================
To/TO
characterize/VB
the/DT
differences/NNS
between/IN
immortalized/VBN
and/CC
transformed/VBD
cells/NNS
,/,
we/PRP
identified/VBD
genes/NNS
that/WDT
were/VBD
differentially/RB
expressed/VBN
among/IN
control/NN
,/,
immortalized/VBN
(/(
c-/NN
====================
myc/JJ
)/)
,/,
and/CC
transformed/VBD
(/(
c-myc+H-ras/NN
V12/NN
)/)
classes/NNS
using/VBG
the/DT
multivariate/JJ
permutation/NN
F-test/JJS
(/(
Simon/JJ
etal./FW
,/,
2004/CD
;/:
Korn/NN
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
The/DT
false/JJ
discovery/NN
rate/NN
(/(
FDR/NN
)/)
was/VBD
defined/VBN
as/IN
the/DT
proportion/NN
of/IN
genes/NNS
reported/VBN
to/TO
be/VB
differentially/RB
expressed/VBN
by/IN
our/PRP$
assay/NN
that/WDT
were/VBD
false/RB
positives/VBZ
./.
====================
We/PRP
used/VBD
the/DT
multivariate/JJ
permutation/NN
test/NN
to/TO
provide/VB
a/DT
95/CD
%/NN
confidence/NN
level/NN
where/WRB
the/DT
false/NN
discovery/NN
rate/NN
(/(
FDR/NN
)/)
was/VBD
less/RBR
than/IN
1/CD
%/NN
./.
====================
Gene/NN
ontology/NN
(/(
GO/NN
)/)
(/(
The/DT
Gene/NN
Ontology/NN
Consortium/NN
,/,
2000/CD
)/)
groups/NNS
of/IN
the/DT
selected/VBN
genes/NNS
were/VBD
identified/VBN
./.
====================
This/DT
GO/NN
analysis/NN
was/VBD
performed/VBN
to/TO
provide/VB
information/NN
regarding/VBG
whether/IN
the/DT
list/NN
of/IN
significant/JJ
genes/NNS
selected/VBN
by/IN
the/DT
analysis/NN
was/VBD
different/JJ
to/TO
a/DT
randomly/RB
generated/VBN
list/NN
selected/VBN
from/IN
all/DT
genes/NNS
in/IN
a/DT
given/VBN
GO/NN
category/NN
./.
====================
This/DT
type/NN
of/IN
analysis/NN
is/VBZ
different/JJ
from/IN
a/DT
simple/JJ
annotation/NN
of/IN
a/DT
gene/NN
list/NN
using/VBG
GO/NN
categories/NNS
./.
====================
The/DT
data/NNS
was/VBD
expressed/VBN
as/IN
the/DT
observed/VBN
vs./CC
the/DT
expected/VBN
ratio/NN
where/WRB
the/DT
observed/VBN
was/VBD
defined/VBN
as/IN
the/DT
number/NN
of/IN
genes/NNS
in/IN
the/DT
list/NN
of/IN
significant/JJ
genes/NNS
which/WDT
fell/JJ
into/IN
a/DT
GO/NN
category/NN
./.
====================
The/DT
expected/VBN
was/VBD
defined/VBN
as/IN
the/DT
average/NN
number/NN
of/IN
genes/NNS
which/WDT
would/MD
be/VB
expected/VBN
to/TO
fall/DT
into/IN
that/DT
GO/NN
category/NN
in/IN
a/DT
subset/NN
of/IN
genes/NNS
randomly/RB
selected/VBN
from/IN
all/DT
genes/NNS
in/IN
the/DT
analysis/NN
./.
====================
A/DT
GO/NN
category/NN
consisted/VBD
of/IN
not/RB
only/RB
the/DT
genes/NNS
which/WDT
were/VBD
described/VBN
by/IN
that/DT
GO/NN
term/NN
,/,
but/CC
also/RB
any/DT
gene/NN
which/WDT
was/VBD
described/VBN
by/IN
any/DT
members/NNS
of/IN
that/DT
GO/NN
term/NN
./.
====================
We/PRP
also/RB
developed/VBD
models/NNS
to/TO
predict/VB
the/DT
class/NN
for/IN
samples/NNS
,/,
where/WRB
the/DT
gene/NN
ontology/NN
is/VBZ
unknown/JJ
./.
====================
Although/IN
the/DT
95/CD
%/NN
confidence/NN
with/IN
FDR/NN
</JJR
0.01/CD
was/VBD
a/DT
strict/JJ
constraint/NN
,/,
the/DT
selected/VBN
genes/NNS
were/VBD
too/RB
numerous/JJ
to/TO
construct/VB
a/DT
prediction/NN
model/NN
./.
====================
We/PRP
performed/VBD
another/DT
feature/NN
selection/NN
step/NN
to/TO
obtain/VB
compact/NN
gene/NN
sets/NNS
for/IN
an/DT
optimal/JJ
prediction/NN
model/NN
./.
====================
Particularly/RB
,/,
we/PRP
used/VBD
a/DT
method/NN
of/IN
gene/NN
selection/NN
utilizing/VBG
support/VBP
vector/NN
methods/NNS
(/(
SVM/NN
)/)
(/(
Vapnik/NN
,/,
1998/CD
)/)
based/VBN
on/IN
recursive/JJ
feature/NN
elimination/NN
(/(
RFE/NN
)/)
(/(
Guyon/NN
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Gene/NN
selection/NN
with/IN
SVM/NN
based/VBN
on/IN
RFE/NN
eliminates/VBZ
gene/NN
redundancy/NN
automatically/RB
and/CC
yields/VBZ
better/RBR
and/CC
more/RBR
compact/NN
gene/NN
subsets/NNS
./.
====================
We/PRP
also/RB
developed/VBD
a/DT
prediction/NN
model/NN
using/VBG
the/DT
Sequential/JJ
Minimal/JJ
Optimization/NN
(/(
SMO/NN
)/)
algorithm/NN
with/IN
a/DT
logistic/JJ
regression/NN
model/NN
and/CC
RBF/NN
kernel/NN
(/(
Platt/NN
,/,
1998/CD
)/)
incorporating/VBG
the/DT
genes/NNS
that/WDT
were/VBD
selected/VBN
by/IN
SVM/NN
based/VBN
on/IN
RFE/NN
./.
====================
We/PRP
estimated/VBD
the/DT
prediction/NN
error/NN
of/IN
each/DT
model/NN
using/VBG
leave-one-out/RB
cross/JJ
-validation/NN
(/(
LOOCV/NN
)/)
,/,
which/WDT
is/VBZ
a/DT
special/JJ
case/NN
of/IN
n-fold/JJ
cross-validation/NN
,/,
where/WRB
n/NN
is/VBZ
the/DT
number/NN
of/IN
samples/NNS
in/IN
the/DT
dataset/NN
(/(
Tan/NNP
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
LOOCV/NN
has/VBZ
the/DT
advantage/NN
of/IN
utilizing/VBG
as/IN
much/RB
data/NNS
as/IN
possible/JJ
for/IN
training/VBG
./.
====================
In/IN
addition/NN
,/,
the/DT
test/NN
sets/NNS
were/VBD
mutually/RB
exclusive/JJ
,/,
and/CC
they/PRP
effectively/RB
covered/VBD
the/DT
entire/JJ
dataset/NN
./.
====================
LOOCV/NN
provided/VBD
a/DT
method/NN
which/WDT
maximized/VBD
the/DT
data/NNS
obtained/VBN
from/IN
a/DT
small/JJ
dataset/NN
and/CC
while/IN
generating/VBG
as/IN
accurate/JJ
an/DT
====================
estimate/NN
as/IN
possible/JJ
(/(
Tan/NN
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
NIH3T3/NN
mouse/NN
fibroblast/NN
cells/NNS
can/MD
be/VB
maintained/VBN
in/IN
monolayer/JJ
cells/NNS
,/,
but/CC
it/PRP
can/MD
not/RB
be/VB
grown/VBN
in/IN
soft/JJ
agar/NN
./.
====================
To/TO
====================
establish/VBP
models/NNS
for/IN
immortalization/NN
and/CC
transformation/NN
,/,
we/PRP
introduced/VBD
c~myc/NN
and/CC
H-ras/NN
V12/NN
expression/NN
plasmid/NN
to/TO
NIH3T3/NN
cells/NNS
and/CC
selected/VBN
stable/JJ
cell/NN
colonies/NNS
as/IN
reported/VBN
previously/RB
(/(
Wiehle/JJ
et/FW
al./FW
,/,
1990/CD
)/)
./.
====================
The/DT
tumorigenic/JJ
potential/JJ
of/IN
NIH3T3/NN
,/,
NIH3T3/NN
(/(
c-myc/NN
)/)
,/,
NIH3T3/NN
(/(
H-ras/NNS
V12/NN
)/)
and/CC
NIH3T3/NN
(/(
c-myc+H-ras/NNS
V12/NN
)/)
cells/NNS
were/VBD
checked/VBN
using/VBG
the/DT
colony/NN
formation/NN
in/IN
soft/JJ
agar/NN
and/CC
tumor/NN
formation/NN
in/IN
vivo/FW
in/IN
Balb/c-nu/NNP
mice/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
We/PRP
compared/VBD
the/DT
tumorigenicity/NN
using/VBG
Vero/FW
and/CC
HeLa/NN
cells/NNS
as/IN
negative/JJ
and/CC
positive/JJ
====================
Table/JJ
1/CD
./.
====================
In/IN
vitro/FW
and/CC
in/IN
vivo/FW
tumorigenicity/NN
assay/NN
for/IN
NIH3T3/NN
,/,
NIH3T3/NN
(/(
c-myc/NN
)/)
,/,
NIH3T3/NN
(/(
H-rasV12/NN
)/)
and/CC
NIH3T3/NN
(/(
c-myc+H-/NN
rasV12/NN
)/)
cells/NNS
./.
====================
controls/NNS
,/,
respectively/RB
./.
====================
Immortalized/VBN
cells/NNS
could/MD
form/VB
a/DT
colony/NN
in/IN
in/FW
vitro/FW
tumorigenicity/NN
assay/NN
,/,
but/CC
not/RB
tumor/NN
mass/NN
in/IN
in/FW
vivo/FW
tumorigenicity/NN
assay/NN
,/,
while/IN
NIH3T3/NN
(/(
H-ras/NNS
V12/NN
)/)
and/CC
NIH3T3/NN
(/(
c-myc+H-ras/NNS
V12/NN
)/)
cells/NNS
could/MD
make/VB
massive/JJ
tumor/NN
in/IN
vivo/FW
as/IN
well/RB
as/IN
in/IN
vitro/FW
./.
====================
We/PRP
identified/VBD
8,751/CD
differentially/RB
expressed/VBN
genes/NNS
from/IN
control/JJ
,/,
immortalized/VBN
,/,
and/CC
transformed/VBD
cells/NNS
through/IN
multivariate/JJ
permutation/NN
F-test/JJS
with/IN
95/CD
%/NN
confidence/NN
and/CC
1/CD
%/NN
false/VBP
discovery/NN
rate/NN
./.
====================
Upon/IN
analysis/NN
of/IN
the/DT
distribution/NN
of/IN
those/DT
genes/NNS
along/IN
the/DT
chromosomes/NNS
,/,
we/PRP
did/VBD
not/RB
find/VB
any/DT
preferential/JJ
locus/NN
among/IN
20/CD
chromosomes/NNS
of/IN
the/DT
mouse/NN
genome/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
These/DT
results/NNS
may/MD
indicate/VB
that/IN
the/DT
transcriptional/JJ
regulations/NNS
of/IN
immortalization/NN
and/CC
transformation/NN
do/VBP
not/RB
ioverlab/NN
./.
====================
To/TO
identify/VB
the/DT
characteristics/NNS
of/IN
the/DT
8,751/CD
genes/NNS
,/,
we/PRP
performed/VBD
gene/NN
ontology/NN
analysis/NN
based/VBN
on/IN
observed/VBN
vs./CC
expected/VBN
ratio/NN
./.
====================
Our/PRP$
analysis/NN
showed/VBD
statistically/RB
overrepresented/VBN
GO/NN
terms/NNS
within/IN
a/DT
group/NN
of/IN
genes/NNS
(/(
Table/JJ
2/CD
)/)
./.
====================
Five/CD
categories/NNS
of/IN
gene/NN
ontology/NN
were/VBD
related/JJ
to/TO
differentially/RB
expressed/VBN
genes/NNS
in/IN
the/DT
immortalization//JJ
transformation/NN
model/NN
./.
====================
Oxidoreductase/JJ
activity/NN
,/,
especially/RB
related/JJ
to/TO
superoxide/VB
radicals/NNS
,/,
was/VBD
altered/JJ
in/IN
our/PRP$
model/NN
./.
====================
This/DT
is/VBZ
likely/JJ
to/TO
be/VB
important/JJ
in/IN
DNA/NN
damage/NN
and/CC
mutagenesis/NN
./.
====================
In/IN
addition/NN
,/,
the/DT
genes/NNS
identified/VBN
that/WDT
have/VBP
nucleotide/NN
kinase/NN
activity/NN
are/VBP
likely/JJ
to/TO
be/VB
important/JJ
in/IN
====================
aberrant/JJ
DNA/NN
synthesis/NN
and/CC
metabolism/NN
predisposing/VBG
cells/NNS
to/TO
transformation/NN
./.
====================
One/CD
of/IN
the/DT
most/JJS
interesting/JJ
categories/NNS
deleted/VBN
involved/VBN
stem/NN
cell/NN
factor/NN
receptor/NN
binding/NN
which/WDT
may/MD
be/VB
representative/JJ
of/IN
cancer/NN
cell/NN
de­/NN
differentiation/NN
in/IN
our/PRP$
model/NN
./.
====================
We/PRP
have/VBP
picked/VBN
several/JJ
genes/NNS
out/RP
of/IN
the/DT
DEG/NN
lists/NNS
to/TO
explain/VB
the/DT
effects/NNS
of/IN
each/DT
oncogenes/NNS
./.
====================
In/IN
particular/JJ
,/,
we/PRP
tested/VBD
four/CD
genes/NNS
,/,
which/WDT
have/VBP
been/VBN
reported/VBN
to/TO
be/VB
targets/NNS
of/IN
c-myc/NN
transcriptional/JJ
regulation/NN
./.
====================
All/DT
of/IN
these/DT
genes/NNS
were/VBD
up-/RB
or/CC
down/RB
regulated/VBN
by/IN
the/DT
expression/NN
of/IN
c-myc/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
,/,
however/RB
,/,
the/DT
expression/NN
of/IN
all/DT
four/CD
genes/NNS
was/VBD
also/RB
affected/VBD
by/IN
the/DT
ectopic/JJ
expression/NN
of/IN
H-ras/NN
V12/NN
./.
====================
In/IN
the/DT
cases/NNS
of/IN
Mina/NN
and/CC
Duspl/NN
,/,
H-ras/NN
V12/NN
induced/VBD
the/DT
expression/NN
of/IN
target/NN
genes/NNS
at/IN
the/DT
level/NN
of/IN
c-myc-dependent/JJ
regulation/NN
./.
====================
The/DT
induction/NN
of/IN
Thbsl/JJ
by/IN
H-ras/NN
V12/NN
was/VBD
higher/JJR
than/IN
that/DT
observed/VBN
for/IN
c-myc/NN
./.
====================
More/RBR
interestingly/RB
,/,
the/DT
transcription/NN
of/IN
Gadd45a/NN
bias/NNS
been/VBN
shown/VBN
to/TO
be/VB
suppressed/VBN
by/IN
c-myc/NN
,/,
while/IN
H-ras/NN
v/LS
12/CD
could/MD
up-regulate/VB
Gadd45a/NN
expression/NN
./.
====================
The/DT
effect/NN
of/IN
H-ras/NN
V12/NN
was/VBD
sufficient/JJ
to/TO
overcome/VB
the/DT
suppression/NN
by/IN
c-myc/NN
and/CC
up-regulate/VBP
the/DT
expression/NN
of/IN
Gadd45a/NN
in/IN
cells/NNS
expressing/VBG
both/CC
c-myc/NN
and/CC
H-ras/NN
V12/NN
./.
====================
Although/IN
we/PRP
picked/VBD
only/RB
four/CD
genes/NNS
from/IN
the/DT
DEG/NN
list/NN
,/,
the/DT
information/NN
on/IN
gene/NN
expression/NN
revealed/VBD
many/JJ
interesting/JJ
====================
regulatory/JJ
relationships/NNS
between/IN
different/JJ
oncogenes/NNS
./.
====================
To/TO
obtain/VB
small/JJ
sets/NNS
of/IN
discriminative/JJ
genes/NNS
,/,
we/PRP
performed/VBD
an/DT
additional/JJ
feature/NN
subset/NN
selection/NN
process/NN
using/VBG
linear/JJ
SVM/NN
based/VBN
on/IN
RFE/NN
and/CC
discovered/VBN
13/CD
informative/JJ
genes/NNS
(/(
Table/JJ
3/CD
)/)
./.
====================
We/PRP
constructed/VBD
a/DT
prediction/NN
model/NN
using/VBG
the/DT
SMO/NN
algorithm/NN
with/IN
a/DT
logistic/JJ
regression/NN
model/NN
and/CC
the/DT
radial/JJ
basis/NN
function/NN
(/(
RBF/NN
)/)
-kemel/JJ
./.
====================
The/DT
performance/NN
of/IN
the/DT
prediction/NN
model/NN
was/VBD
assessed/VBN
using/VBG
LOOCV/NN
and/CC
was/VBD
found/VBN
to/TO
be/VB
one/CD
hundred/VBN
percent/NN
accurate/JJ
for/IN
the/DT
data/NNS
analyzed/VBD
./.
====================
We/PRP
also/RB
validated/VBD
our/PRP$
prediction/NN
model/NN
using/VBG
microarray/NN
data/NNS
from/IN
four/CD
H-ras-transfected/JJ
transformed/VBN
cell/NN
lines/NNS
and/CC
they/PRP
were/VBD
correctly/RB
classified/VBN
as/IN
a/DT
transformed/VBN
class/NN
./.
====================
In/IN
order/NN
to/TO
visualize/VB
selected/VBN
biomarkers/NNS
,/,
we/PRP
performed/VBD
hierarchical/JJ
clustering/NN
of/IN
13/CD
gene/NN
with/IN
average/JJ
linkage/NN
and/CC
Manhattan/JJ
distance/NN
measures/NNS
for/IN
a/DT
total/JJ
16/CD
sets/NNS
of/IN
microarray/NN
data/NNS
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
The/DT
heat/NN
map/VBP
illustrated/JJ
that/DT
data/NNS
====================
from/IN
H-ras/NN
v12/NN
-transfected/JJ
transformed/VBN
cell/NN
(/(
H-ras/NN
V12/NN
)/)
data/NNS
were/VBD
closely/RB
clustered/VBN
with/IN
c-myc+H-ras/NN
vi2/NN
calss/NN
./.
====================
We/PRP
have/VBP
created/VBN
composite/JJ
profiles/NNS
for/IN
an/DT
in/FW
vitro/FW
====================
immortalization/NN
and/CC
transformation/NN
model/NN
,/,
which/WDT
was/VBD
====================
confirmed/VBD
by/IN
in/FW
vivo/FW
tumorigenecity/NN
assays/NNS
./.
====================
Using/VBG
the/DT
multivariate/JJ
permutation/NN
F-test/JJS
(/(
95/CD
%/NN
confidence/NN
,/,
FDR/NN
</JJR
0.01/CD
)/)
,/,
we/PRP
found/VBD
8,751/CD
differentially/RB
expressed/VBN
genes/NNS
for/IN
our/PRP$
immortalization/transformation/NN
model/NN
./.
====================
In/IN
c-myc-/NN
transfected/VBN
“/NN
immortalized/VBN
”/CD
cells/NNS
,/,
we/PRP
found/VBD
signatures/NNS
of/IN
known/VBN
immortalization/NN
markers/NNS
related/JJ
to/TO
telomere/VB
and/CC
transforming/VBG
growth/NN
factor/NN
signaling/NN
./.
====================
A/DT
comparison/NN
of/IN
the/DT
known/JJ
targets/NNS
for/IN
c-myc/NN
revealed/VBD
that/IN
many/JJ
were/VBD
also/RB
====================
regulated/VBN
by/IN
H-ras/NN
V12/NN
./.
====================
In/IN
the/DT
case/NN
of/IN
Gadd45a/NN
,/,
c-myc/NN
alone/RB
could/MD
suppress/VB
its/PRP$
expression/NN
while/IN
the/DT
co-expression/NN
of/IN
H-ras/NN
V12/NN
caused/VBD
a/DT
reversal/JJ
of/IN
this/DT
suppression/NN
./.
====================
To/TO
enhance/VB
the/DT
power/JJ
of/IN
analysis/NN
of/IN
this/DT
sysem/NN
,/,
more/RBR
profiles/NNS
on/IN
cell/NN
lines/NNS
and/CC
cancer/NN
tissues/NNS
need/VBD
to/TO
be/VB
divulged/VBN
./.
====================
Based/VBN
on/IN
the/DT
wrapper/NN
approach/NN
we/PRP
were/VBD
able/JJ
to/TO
select/VB
13/CD
genes/NNS
to/TO
establish/VB
a/DT
prediction/NN
model/NN
for/IN
immortalization/NN
and/CC
transformation/NN
,/,
which/WDT
gave/VBD
perfect/JJ
accuracy/NN
in/IN
calssifying/JJ
====================
H-ras/NN
v12/NN
-transfected/JJ
cells/NNS
as/IN
a/DT
transformed/VBN
class/NN
./.
====================
